Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
Leapmotor Targets 4 Million Annual EV Sales as Global Expansion Accelerates 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
Elon Musk’s xAI Expands Supercomputer Infrastructure With Third Data Center to Boost AI Training Power 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
PHILADELPHIA and OXFORD, United Kingdom, March 02, 2017 -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that James Noble, Adaptimmune’s Chief Executive Officer, will present at the Cowen and Company 37th Annual Health Care Conference on Tuesday March 7, 2017 at 10:40-11:10 AM EST (3:40-4:10 PM GMT). The conference is being held at the Boston Marriott Copley Plaza. Adaptimmune’s presentation will be webcast live for investors through the investor section of www.adaptimmune.com and available for a period of 30 days following the conference.
About Adaptimmune
Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products. The Company’s unique SPEAR® (Specific Peptide Enhanced Affinity Receptor) T‑cell platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. Adaptimmune has a number of proprietary clinical programs, and is also developing its NY-ESO SPEAR T-cell program under a strategic collaboration and licensing agreement with GlaxoSmithKline. The Company is located in Philadelphia, USA and Oxfordshire, U.K. For more information, please visit http://www.adaptimmune.com
Adaptimmune Contacts Investor Relations Will Roberts T: (215) 825-9306 E: [email protected] Juli P. Miller, Ph.D. T: (215) 825-9310 E: [email protected] Media Relations Margaret Henry T: +44 (0)1235 430036 Mobile: +44 (0)7710 304249 E: [email protected]
